There is no single best treatment for lupus. The disease varies so widely from person to person that treatment follows a layered approach, starting with a foundation drug recommended for nearly every patient and adding stronger therapies only when needed. The 2023 EULAR guidelines lay out this step-by-step strategy clearly, and understanding it can help you make sense of what your treatment team is doing and why.
Hydroxychloroquine: The Foundation for Everyone
Hydroxychloroquine is the closest thing lupus treatment has to a universal recommendation. International guidelines call for it in all patients with systemic lupus unless there’s a specific reason they can’t take it. It reduces flares, protects organs over the long term, lowers the risk of blood clots, and may even improve survival. The recommended dose is 5 mg per kilogram of your actual body weight per day, a threshold set partly to minimize the risk of eye damage with long-term use.
The drug works by calming the overactive immune signaling that drives lupus, but it’s not a quick fix. Most people need several weeks to months before they notice its full effect. Because hydroxychloroquine is a long-term (often lifelong) medication, regular eye screening is important. The American Academy of Ophthalmology recommends a baseline eye exam soon after starting the drug, including retinal imaging with optical coherence tomography. Annual screening follows, though it can often be deferred during the first five years if you have no additional risk factors for retinal toxicity. More frequent checks are warranted if risk factors are present.
Steroids: Powerful but Temporary
When lupus flares, corticosteroids like prednisone can bring inflammation under control fast. But they come with serious long-term costs, including bone thinning, weight gain, high blood sugar, and organ damage that accumulates over years. That’s why current guidelines treat steroids as a bridge, not a destination. The goal is always to taper down and, ideally, stop them entirely.
Research from the RELES cohort found that average prednisone doses above 7.5 mg per day during the first year of disease significantly increase measurable organ damage within five years. That 7.5 mg threshold is now widely recognized as the ceiling for maintenance dosing. If you’re on a higher daily dose for more than a few months, your treatment team should be exploring ways to bring it lower, usually by adding a steroid-sparing medication. The prednisone dose you take in your first month of treatment tends to predict your total steroid exposure over the following year, which makes early, aggressive tapering especially important.
Immunosuppressive Medications
When hydroxychloroquine alone isn’t enough to control symptoms or when steroids can’t be reduced to a safe level, immunosuppressive drugs are the next step. The most commonly used options include methotrexate, azathioprine, and mycophenolate. Which one your doctor chooses depends largely on which organs are affected and how severe your disease is.
Mycophenolate is a cornerstone of treatment for lupus nephritis, the form of lupus that attacks the kidneys. For joint and skin involvement without major organ threat, methotrexate or azathioprine are common choices. These drugs suppress the parts of the immune system driving lupus activity, which means they also lower your ability to fight infections. Regular blood work to monitor your immune cell counts and liver and kidney function is a standard part of staying on these medications safely.
Biologic Therapies
Two biologic drugs are now approved specifically for lupus, and they represent a meaningful advance for people whose disease doesn’t respond well to traditional immunosuppressants.
Belimumab (Benlysta) works by blocking a protein that helps certain immune cells survive longer than they should. In a large pooled analysis of clinical trials, 55% of patients on belimumab achieved a meaningful improvement in disease activity at one year, compared with 42% on placebo. That benefit held regardless of how long someone had lived with lupus or what other medications they were taking. For people with early, active disease, response rates were even higher, reaching 57 to 58%.
Anifrolumab (Saphnelo) takes a different approach, blocking a signaling pathway driven by a group of immune molecules called type I interferons. Many lupus patients have elevated interferon activity, and shutting it down can reduce skin rashes, joint pain, and overall disease activity. Both biologics are typically added on top of existing medications rather than used alone.
Treating Lupus Nephritis
Kidney involvement is one of the most serious complications of lupus and requires its own treatment strategy. The standard approach combines mycophenolate or low-dose intravenous cyclophosphamide with corticosteroids. On top of this foundation, newer add-on therapies can significantly boost the chances of getting kidney function back to normal.
Voclosporin is one such add-on. Pooled data from the AURA-LV and AURORA 1 trials showed that adding voclosporin to standard therapy nearly doubled the rate of complete kidney response at one year: 43.7% achieved it with voclosporin versus 23.3% without. Belimumab and tacrolimus are also used as add-on options. The shift in recent years has been toward combining these agents early rather than waiting to see if standard therapy works on its own.
For the most severe or life-threatening lupus, including rapidly worsening kidney disease or dangerous inflammation in the brain or blood vessels, cyclophosphamide given intravenously remains an option. Rituximab, which depletes a specific type of immune cell, is typically reserved for cases that haven’t responded to other treatments.
CAR-T Cell Therapy: A New Frontier
Perhaps the most striking development in lupus treatment is the early use of CAR-T cell therapy, a technique originally developed for blood cancers. In a study published by researchers at Friedrich-Alexander University in Germany, eight lupus patients received a single infusion of engineered immune cells designed to eliminate the B cells driving their disease. All eight went into remission, and none relapsed during monitoring periods of up to two years.
This is still in early-phase trials, with safety and optimal dosing as primary goals. The treatment requires a process similar to chemotherapy to prepare the body, and it’s currently only being studied in people with severe, treatment-resistant disease. But for patients who have failed multiple medications, the prospect of drug-free remission from a single infusion is remarkable. Larger trials are underway to determine whether these results hold up in broader groups of patients.
Protecting Your Heart
Lupus itself is a significant risk factor for heart disease. The chronic inflammation that defines the condition accelerates the buildup of plaque in arteries, and the ACC/AHA prevention guidelines formally list lupus as a cardiovascular risk enhancer. In practical terms, this means your lupus diagnosis should factor into decisions about cholesterol management and whether you might benefit from a statin, even if your standard risk scores look borderline.
One challenge is that conventional heart risk calculators weren’t designed for lupus patients and tend to underestimate their actual risk. Newer lupus-specific risk tools use different thresholds, with some flagging moderate risk at 7.5% rather than the standard 5%. When the decision is uncertain, coronary artery calcium scoring (a quick CT scan of the heart) can help clarify whether preventive treatment makes sense for you.
Sun Protection and Lifestyle
Ultraviolet light is one of the most reliable lupus triggers, capable of sparking both skin flares and systemic disease activity. Broad-spectrum sunscreen with SPF 30 or higher is the minimum recommendation, applied to all exposed skin, including often-missed areas like the scalp and ears. Sunscreen effectiveness drops after about two hours, so reapplication is essential during prolonged time outdoors. Water-resistant formulas lose effectiveness after swimming or sweating.
Beyond sunscreen, staying indoors during peak UV hours (10 a.m. to 4 p.m.), seeking shade, and wearing UV-protective clothing, hats, and umbrellas all reduce your exposure meaningfully. These aren’t minor lifestyle suggestions. For many people with lupus, consistent sun protection is as important as any medication in preventing flares.
How Treatment Is Layered Over Time
The overall strategy works like a staircase. Hydroxychloroquine is the bottom step for nearly everyone. If that’s not enough, an immunosuppressive drug is added. If steroids are needed to control a flare, the priority shifts to tapering them below 7.5 mg per day as quickly as the disease allows. If conventional immunosuppressants aren’t doing the job, biologics like belimumab or anifrolumab are layered in. For kidney disease, early combination therapy is now preferred. And for the most refractory cases, options like rituximab or, potentially, CAR-T cell therapy come into play.
What makes lupus treatment complex is that no two patients follow the same path through these steps. Your treatment plan depends on which organs are involved, how active the disease is, how you respond to each medication, and what side effects you can tolerate. The “best” treatment is the combination that controls your specific disease with the fewest long-term consequences.